Innovations in Small Interfering RNA (siRNA) Therapy
Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management
EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients
EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment
Now Viewing
EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy
EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data
EP: 6.Evaluating Safety of Novel LDL Management Mechanism
Related Videos
Related Content
